## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.5% below STRENGTH zone (3.0-6.0%); PEG 3.31 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($269.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements**
- Source: TradingView | 20251208T130854 | Bullish | Relevance: 98%
-  Insulet Corporation (PODD) recently received FDA clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System, including a lower 100 mg/dL Target Glucose option and improved automation. This development is expected to strengthen Insulet's market leadership and maintain positive market sentiment for PODD stock. The company's innovative efforts and expansion of the Omnipod 5 platform are anticipated to drive continued growth in the diabetes management market.

**2. Insider Buying: Timothy Stonesifer Acquires Shares of Insulet Co**
- Source: GuruFocus | 20251208T222951 | Somewhat-Bullish | Relevance: 98%
-  On December 5, 2025, Timothy Stonesifer, a Director at Insulet Corp (PODD), purchased 962 shares, increasing his total holdings to 4,591 shares. This transaction marks the sole insider buy for the company in the past year, contrasting with 14 insider sells. Insulet Corp's stock was trading at $311.73, and with a GF Value of $364.27, it is considered modestly undervalued.

**3. Insulet Corporation $PODD Shares Sold by Brown Advisory Inc.**
- Source: MarketBeat | 20251208T092619 | Neutral | Relevance: 98%
-  Brown Advisory Inc. reduced its stake in Insulet Corporation by 20.4% in the second quarter, selling 7,483 shares. Despite a revenue miss, Insulet reported strong EPS of $1.24, exceeding estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $379.65. Several other institutional investors also adjusted their holdings in PODD.

**4. Federated Hermes Inc. Grows Position in Insulet Corporation $PODD**
- Source: MarketBeat | 20251207T120825 | Somewhat-Bullish | Relevance: 97%
-  Federated Hermes Inc. increased its stake in Insulet Corporation (NASDAQ:PODD) by 14.3% in the second quarter, now holding 723,363 shares valued at over $227 million. Several other institutional investors also adjusted their positions in Insulet, whose stock performance shows a market cap of $21.42 billion and recent quarterly earnings exceeding analyst estimates. Insider transactions by SVPs Prem Singh and Laetitia Cousin involved significant share sales, while multiple analysts issued "Buy" or "Overweight" ratings and increased price targets for the company.

**5. Insulet (NASDAQ:PODD) Shareholders YoY Returns Are Lagging the Company's 8.5% Five-year Earnings Growth**
- Source: 富途牛牛 | 20251207T150944 | Neutral | Relevance: 97%
-  Insulet Corporation (NASDAQ:PODD) shareholders have seen their stock price return 27% over five years, which is less than the market return of 82%. Despite impressive compound earnings per share (EPS) growth of 51% per year during this period, the share price only increased by 5% annually, suggesting the market has become more cautious towards the stock, even with its current P/E ratio of 87.00. The article highlights a disconnect between the company's strong underlying earnings performance and its comparatively modest share price appreciation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |
| 2025-11-21 | Truist Securiti | $412 | $390 | +6% |
| 2025-11-21 | RBC Capital | $380 | $370 | +3% |
| 2025-11-21 | BTIG | $380 | $370 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Canaccord Genui | main | Buy |
| 2025-11-21 | Truist Securiti | main | Buy |
| 2025-11-21 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Valuation stretched: PEG 3.3x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.31 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 20% YoY. Insider buying signal ($0.5M), management confidence. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.31 |
| Forward P/E | 47.7 |
| Current P/E | 60.1 |
| YoY Growth | 26.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 9.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. MACD histogram bearish (-3.76), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.49% (CS: 4) | Weak |
| RSI_14 | 36.9 | Neutral |
| MACD Histogram | -3.76 | Bearish |
| vs SMA20 | 0.914x | Below |
| vs SMA50 | 0.921x | Below |
| vs SMA200 | 0.978x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $294.20
- **Stop Loss:** $269.96 (8.2% risk)
- **Target:** $318.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $3,530.40
- **Portfolio %:** 3.53%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*